Results 191 to 200 of about 13,156 (215)

Treatment of neuromyelitis optica spectrum disorders

Current Opinion in Rheumatology, 2019
Purpose of review This review discusses concepts for diagnosing neuromyelitis optica spectrum disorders (NMOSD), distinguishing NMOSD from other inflammatory diseases of the central nervous system, and highlights recent and forthcoming data on acute and maintenance therapy of NMOSD.
Andrew R, Romeo, Benjamin M, Segal
openaire   +2 more sources

Imaging of Neuromyelitis Optica Spectrum Disorders

Seminars in Ultrasound, CT and MRI, 2020
Neuromyelitis optica (NMO) is a rare and chronic disabling autoimmune astrocytopathy of the central nervous system. Current advances regarding aquaporin-4 antibody function facilitate the understanding of clinical manifestations and imaging findings beyond optic neuritis and transverse myelitis.
openaire   +2 more sources

Neuromyelitis optica spectrum disorders in Iran

Multiple Sclerosis and Related Disorders, 2017
Neuromyelitys optica spectrum disorder (NMOSD) is a rare demyelinating disease; as a result, the epidemiological data on this disorder is scarce. In this regard, the aim of this study was to estimate the prevalence, serology, and clinical features of NMOSD in Caucasian population in Tehran, Iran.A cross sectional study was performed in Tehran from 2015
Sharareh, Eskandarieh, Saharnaz, Nedjat, Amir Reza, Azimi, Abdorreza Naser, Moghadasi, Mohammad Ali, Sahraian   +4 more
openaire   +2 more sources

Neuromyelitis Optica Spectrum Disorders

Journal of Immunological Techniques & Infectious Diseases, 2018
Corinna Trebst, Ilya Ayzenberg, Ingo Kleiter   +2 more
openaire   +2 more sources

Biotinidase Deficiency as a Mimic of Neuromyelitis Optica Spectrum Disorder in Childhood

JAMA Neurology, 2021
Jonathan D Santoro
exaly  

New therapies for neuromyelitis optica spectrum disorder

Lancet Neurology, The, 2021
Michael Levy, Kazuo Fujihara, Jacqueline Palace   +2 more
exaly  

Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial

Multiple Sclerosis Journal, 2022
Mary R Rensel, Aram Zabeti, Maureen A Mealy   +2 more
exaly  

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Lancet, The, 2019
Petra Nytrova, Jeffrey L Bennett, Ho Jin Kim   +2 more
exaly  

Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

New England Journal of Medicine, 2019
Takashi Yamamura, Ingo Kleiter, Kazuo Fujihara   +2 more
exaly  

Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

New England Journal of Medicine, 2019
Sean J Pittock, Achim Berthele, Kazuo Fujihara   +2 more
exaly